The vascular endothelial growth factor (VEGF)-E encoded by orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration

Cellular Microbiology

Volumn 14, Issue 9, 2012, Pages 1376-1390

  Wise, Lyn M ^a   Inder, Marie K ^a   Real, Nicola C ^a   Stuart, Gabriella S ^a   Fleming, Stephen B ^a   Mercer, Andrew A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; KERATINOCYTE GROWTH FACTOR; NEUTRALIZING ANTIBODY; SCATTER FACTOR; STROMELYSIN; VASCULOTROPIN A; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DERMIS; ENDOTHELIUM CELL; EPIDERMIS; EPITHELIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REEPITHELIALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BLOOD VESSEL; SKIN INJURY; SKINFOLD THICKNESS; TISSUE REGENERATION; VIRAL SKIN DISEASE; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; EPIDERMIS; GENE EXPRESSION PROFILING; KERATINOCYTES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; ORF VIRUS; REAL-TIME POLYMERASE CHAIN REACTION; REGENERATION; VIRAL PROTEINS; VIRULENCE FACTORS;

ORF VIRUS; PARAPOXVIRUS;

EID: 84865315860     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2012.01802.x     Document Type: Article

References (75)

1. Ando, Y., and Jensen, P.J. (1993) Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration. J Invest Dermatol 100: 633-639.
2. Arroyo, A.G., and Iruela-Arispe, M.L. (2010) Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res 86: 226-235.
3. Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H., and Tomic-Canic, M. (2008) Growth factors and cytokines in wound healing. Wound Repair Regen 16: 585-601.
4. Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A., and Fusenig, N.E. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771.
5. Brem, H., Kodra, A., Golinko, M.S., Entero, H., Stojadinovic, O., Wang, V.M., etal. (2009) Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol 129: 2275-2287.
6. Brown, L.F., Yeo, K.T., Berse, B., Yeo, T.K., Senger, D.R., Dvorak, H.F., and van de Water, L. (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176: 1375-1379.
7. Brown, L.F., Olbricht, S.M., Berse, B., Jackman, R.W., Matsueda, G., Tognazzi, K.A., etal. (1995) Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 154: 2801-2807.
8. Canavese, M., Altruda, F., Silengo, L., Castiglioni, V., Scanziani, E., and Radaelli, E. (2011) Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice. Histol Histopathol 26: 285-296.
9. Carmeliet, P. (2000) VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 6: 1102-1103.
10. Carmeliet, P., and Jain, R.K. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
11. Detmar, M. (2004) Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol 122: xiv-xxv.
12. Ebrahem, Q., Chaurasia, S.S., Vasanji, A., Qi, J.H., Klenotic, P.A., Cutler, A., etal. (2010) Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo Am J Pathol 176: 496-503.
13. Elias, P.M., Arbiser, J., Brown, B.E., Rossiter, H., Man, M.Q., Cerimele, F., etal. (2008) Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol 173: 689-699.
14. Eppihimer, M.J., Russell, J., Langley, R., Vallien, G., Anderson, D.C., and Granger, D.N. (1998) Differential expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) in murine tissues. Microcirculation 5: 179-188.
15. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
16. Fujita, M., Furukawa, F., Fujii, K., Horiguchi, Y., Takeichi, M., and Imamura, S. (1992) Expression of cadherin cell adhesion molecules during human skin development: morphogenesis of epidermis, hair follicles and eccrine sweat ducts. Arch Dermatol Res 284: 159-166.
17. Gosselet, F.P., Magnaldo, T., Culerrier, R.M., Sarasin, A., and Ehrhart, J.C. (2007) BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. Cell Signal 19: 731-739.
18. Groves, R.W., Wilson-Jones, E., and MacDonald, D.M. (1991) Human orf and milkers' nodule: a clinicopathologic study. J Am Acad Dermatol 25: 706-711.
19. Gurel, M.S., Ozardali, I., Bitiren, M., San, I., and Zeren, H. (2002) Giant orf on the nose. Eur J Dermatol 12: 183-185.
20. Haig, D.M., and Mercer, A.A. (1998) Ovine diseases. Orf. Vet Res 29: 311-326.
21. Holmes, K., Roberts, O.L., Thomas, A.M., and Cross, M.J. (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012.
22. Hunskaar, S. (1986) Giant orf in a patient with chronic lymphocytic leukaemia. Br J Dermatol 114: 631-634.
23. Inder, M.K., Ueda, N., Mercer, A.A., Fleming, S.B., and Wise, L.M. (2007) Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2. J Gen Virol 88: 781-791.
24. Inder, M.K., Wise, L.M., Fleming, S.B., and Mercer, A.A. (2008) The C-terminus of viral vascular endothelial growth factor-E partially blocks binding to VEGF receptor-1. FEBS J 275: 207-217.
25. Inoue, N., Kondo, T., Kobayashi, K., Aoki, M., Numaguchi, Y., Shibuya, M., and Murohara, T. (2007) Therapeutic angiogenesis using novel vascular endothelial growth factor-E/human placental growth factor chimera genes. Arterioscler Thromb Vasc Biol 27: 99-105.
26. Jenkinson, D.M., McEwan, P.E., Moss, V.A., Elder, H.Y., and Reid, H.W. (1990) Location and spread of orf virus antigen in infected ovine skin. Vet Dermatol 1: 189-195.
27. Jensen, P.J., and Wheelock, M.J. (1996) The relationships among adhesion, stratification and differentiation in keratinocytes. Cell Death Differ 3: 357-371.
28. Kaiser, S., Schirmacher, P., Philipp, A., Protschka, M., Moll, I., Nicol, K., and Blessing, M. (1998) Induction of bone morphogenetic protein-6 in skin wounds. Delayed reepitheliazation and scar formation in BMP-6 overexpressing transgenic mice. J Invest Dermatol 111: 1145-1152.
29. Kiba, A., Sagara, H., Hara, T., and Shibuya, M. (2003) VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun 301: 371-377.
30. Koch, S. (2012) Neuropilin signalling in angiogenesis. Biochem Soc Trans 40: 20-25.
31. Koch, S., Tugues, S., Li, X., Gualandi, L., and Claesson-Welsh, L. (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem J 437: 169-183.
32. Kurschat, P., Bielenberg, D., Rossignol-Tallandier, M., Stahl, A., and Klagsbrun, M. (2006) Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration. J Biol Chem 281: 2721-2729.
33. Kyriakides, T.R., Wulsin, D., Skokos, E.A., Fleckman, P., Pirrone, A., Shipley, J.M., etal. (2009) Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol 28: 65-73.
34. Lateef, Z., Baird, M.A., Wise, L.M., Young, S., Mercer, A.A., and Fleming, S.B. (2010) The chemokine-binding protein encoded by the poxvirus orf virus inhibits recruitment of dendritic cells to sites of skin inflammation and migration to peripheral lymph nodes. Cell Microbiol 12: 665-676.
35. Li, C., Man, X., Li, W., Zhou, J., Chen, J., Cai, S., and Zheng, M. (2011) Regulation of adhesion by vascular endothelial growth factor in HaCaT cells. Mol Cell Biochem 346: 173-178.
36. Li, Y., Hazarika, S., Xie, D., Pippen, A.M., Kontos, C.D., and Annex, B.H. (2007) In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 56: 656-665.
37. McColl, B.K., Stacker, S.A., and Achen, M.G. (2004) Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 112: 463-480.
38. Macri, L., Silverstein, D., and Clark, R.A. (2007) Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 59: 1366-1381.
39. Makela, M., Larjava, H., Pirila, E., Maisi, P., Salo, T., Sorsa, T., and Uitto, V.J. (1999) Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell Res 251: 67-78.
40. Man, X.Y., Yang, X.H., Cai, S.Q., Yao, Y.G., and Zheng, M. (2006) Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med 12: 127-136.
41. Man, X.Y., Yang, X.H., Cai, S.Q., Bu, Z.Y., Wu, X.J., Lu, Z.F., and Zheng, M. (2009) Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence. Clin Exp Dermatol 34: 396-401.
42. Matsumoto, K., Hashimoto, K., Yoshikawa, K., and Nakamura, T. (1991) Marked stimulation of growth and motility of human keratinocytes by hepatocyte growth factor. Exp Cell Res 196: 114-120.
43. Michaels, J., Dobryansky, M., Galiano, R.D., Bhatt, K.A., Ashinoff, R., Ceradini, D.J., and Gurtner, G.C. (2005) Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration. Wound Repair Regen 13: 506-512.
44. Mott, J.D., and Werb, Z. (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16: 558-564.
45. Nissen, N.N., Polverini, P.J., Koch, A.E., Volin, M.V., Gamelli, R.L., and DiPietro, L.A. (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152: 1445-1452.
46. Niu, J., Chang, Z., Peng, B., Xia, Q., Lu, W., Huang, P., etal. (2007) Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem 282: 6001-6011.
47. Olsson, A.K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
48. Rheinwald, J.G., and Green, H. (1977) Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 265: 421-424.
49. Robson, M.C., Phillips, T.J., Falanga, V., Odenheimer, D.J., Parish, L.C., Jensen, J.L., and Steed, D.L. (2001) Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9: 347-352.
50. Romano Di Peppe, S., Mangoni, A., Zambruno, G., Spinetti, G., Melillo, G., Napolitano, M., and Capogrossi, M.C. (2002) Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther 9: 1271-1277.
51. Rossiter, H., Barresi, C., Pammer, J., Rendl, M., Haigh, J., Wagner, E.F., and Tschachler, E. (2004) Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res 64: 3508-3516.
52. Salo, T., Makela, M., Kylmaniemi, M., Autio-Harmainen, H., and Larjava, H. (1994) Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 70: 176-182.
53. Savage, J., and Black, M.M. (1972) 'Giant' orf of finger in a patient with a lymphoma. Proc R Soc Med 65: 766-768.
54. Savory, L.J., Stacker, S.A., Fleming, S.B., Niven, B.E., and Mercer, A.A. (2000) Viral vascular endothelial growth factor plays a critical role in orf virus infection. J Virol 74: 10699-10706.
55. Shibuya, M. (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9: 225-230.
56. Sivamani, R.K., Garcia, M.S., and Isseroff, R.R. (2007) Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci 12: 2849-2868.
57. Sogabe, Y., Abe, M., Yokoyama, Y., and Ishikawa, O. (2006) Basic fibroblast growth factor stimulates human keratinocyte motility by Rac activation. Wound Repair Regen 14: 457-462.
58. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
59. Soker, S., Miao, H.Q., Nomi, M., Takashima, S., and Klagsbrun, M. (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85: 357-368.
60. Sweeney, P., Karashima, T., Kim, S.J., Kedar, D., Mian, B., Huang, S., etal. (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8: 2714-2724.
61. Tan, S.T., Blake, G.B., and Chambers, S. (1991) Recurrent orf in an immunocompromised host. Br J Plast Surg 44: 465-467.
62. Vadasz, Z., Attias, D., Kessel, A., and Toubi, E. (2010) Neuropilins and semaphorins - from angiogenesis to autoimmunity. Autoimmun Rev 9: 825-829.
63. Vallien, G., Langley, R., Jennings, S., Specian, R., and Granger, D.N. (2000) Expression of endothelial cell adhesion molecules in neovascularized tissue. Microcirculation 7: 249-258.
64. Wagner, S., Fueller, T., Hummel, V., Rieckmann, P., and Tonn, J.C. (2003) Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC). J Neurooncol 62: 221-231.
65. Weninger, W., Uthman, A., Pammer, J., Pichler, A., Ballaun, C., Lang, I.M., etal. (1996) Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 75: 647-657.
66. Wilgus, T.A., Matthies, A.M., Radek, K.A., Dovi, J.V., Burns, A.L., Shankar, R., and DiPietro, L.A. (2005) Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 167: 1257-1266.
67. Wise, L.M., Veikkola, T., Mercer, A.A., Savory, L.J., Fleming, S.B., Caesar, C., etal. (1999) Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 96: 3071-3076.
68. Wise, L.M., Ueda, N., Dryden, N.H., Fleming, S.B., Caesar, C., Roufail, S., etal. (2003) Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. J Biol Chem 278: 38004-38014.
69. Wise, L., McCaughan, C., Tan, C.K., Mercer, A.A., and Fleming, S.B. (2007a) Orf virus interleukin-10 inhibits cytokine synthesis in activated human THP-1 monocytes, but only partially impairs their proliferation. J Gen Virol 88: 1677-1682.
70. Wise, L.M., Savory, L.J., Dryden, N.H., Whelan, E.M., Fleming, S.B., and Mercer, A.A. (2007b) Major amino acid sequence variants of viral vascular endothelial growth factor are functionally equivalent during Orf virus infection of sheep skin. Virus Res 128: 115-125.
71. Xia, Y.P., Li, B., Hylton, D., Detmar, M., Yancopoulos, G.D., and Rudge, J.S. (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102: 161-168.
72. Xue, M., Le, N.T., and Jackson, C.J. (2006) Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 10: 143-155.
73. Yang, X.H., Man, X.Y., Cai, S.Q., Yao, Y.G., Bu, Z.Y., and Zheng, M. (2006) Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun 349: 31-38.
74. Zheng, Y., Murakami, M., Takahashi, H., Yamauchi, M., Kiba, A., Yamaguchi, S., etal. (2006) Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26: 2019-2026.
75. Zheng, Y., Watanabe, M., Kuraishi, T., Hattori, S., Kai, C., and Shibuya, M. (2007) Chimeric VEGF-ENZ7/PlGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization. Arterioscler Thromb Vasc Biol 27: 503-511.